glp-1 receptor agonist long term side effects The expanding role of agonists: a narrative review of current evidence and future directions Mapping the effectiveness and risks

Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study

There are several types of AN, including benign, obesity-associated, syndromic, malignant, acral, unilateral, medication-induced, and mixed forms [37]

What works for one person might not work for another, so individual choice and professional guidance are necessary

In the late 2000s, still haunted by the fallout from drugs like rosiglitazone (brand name Avandia), linked to increased heart attack risk, the FDA laid down a blunt new rule: every new diabetes drug must prove it wont harm the heart before it ever sees pharmacy shelves

c in patients with concurrent T2DM

Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus